The present technology generally relates to methods, systems, and devices for stimulating cardiac tissue, and more particularly to implantable stimulation assemblies with tissue engagement mechanisms for engaging tissue.
Electrical stimulation of body tissue is used throughout medicine for treatment of both chronic and acute conditions. Among many examples, peripheral muscle stimulation is reported to accelerate healing of strains and tears, bone stimulation is likewise indicated to increase the rate of bone regrowth/repair in fractures, and nerve stimulation is used to alleviate chronic pain. Further there is encouraging research in the use of electrical stimulation to treat a variety of nerve and brain conditions, such as essential tremor, Parkinson's disease, migraine headaches, functional deficits due to stroke, and epileptic seizures.
Cardiac pacemakers and implantable defibrillators are examples of commonly implanted device utilizing electrical stimulation to stimulate cardiac and other tissues. A pacemaker is a battery-powered electronic device implanted under the skin, connected to the heart by an insulated metal lead wire with a tip electrode. Pacemakers were initially developed for and are most commonly used to treat slow heart rates (bradycardia), which may result from a number of conditions. More recently, advancements in pacemaker complexity, and associated sensing and pacing algorithms have allowed progress in using pacemakers for the treatment of other conditions, notably heart failure (HF) and fast heart rhythms (tachyarrhythmia/tachycardia).
Electrical energy sources connected to electrode/lead wire systems have typically been used to stimulate tissue within the body. The use of lead wires is associated with significant problems such as complications due to infection, lead failure, and electrode/lead dislodgement. The requirement for leads to accomplish stimulation also limits the number of accessible locations in the body. The requirement for leads has also limited the ability to stimulate at multiple sites (multisite stimulation).
Wireless stimulation electrodes are often secured to target tissue by pushing an anchor mechanism of the electrode into the tissue to secure the electrode thereto. However, when the target tissue has a complex structure—such as when the tissue is endocardial wall tissue consisting of complex trabeculae, papillary muscles, chordae, etc.—pushing the electrode into the tissue may improperly secure the electrode to the tissue.
Many aspects of the present disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on clearly illustrating the principles of the present disclosure.
Aspects of the present disclosure are directed generally to implantable stimulation assemblies (which can be referred to as receiver-stimulators, stimulation electrodes, pacing electrodes, and the like) including mechanisms for engaging tissue of a patient, such as endocardial tissue, and associated systems and methods. In several of the embodiments described below, for example, a stimulation assembly includes a body, circuitry positioned at least partially within the body, an electrode coupled to the body, and a hook mechanism coupled to the body. The circuitry can be configured to receive acoustic energy and convert the acoustic energy to electrical energy, and the electrode can deliver the electrical energy to the tissue of the patient. The hook mechanism can be configured to engage the tissue to pull the tissue and the electrode toward and into engagement with one another. For example, where the tissue is a portion of an endocardial wall of the heart of the patient, the hook mechanism can have a curved shape configured to engage the complex anatomy of the endocardial wall to pull the electrode into contact with the endocardial wall to facilitate cardiac pacing.
Additional aspects of the present disclosure are directed generally to methods and systems for implanting stimulation assemblies. In several of the embodiments described below, for example, a method of implanting a stimulation assembly at a target site of tissue within a patient includes threading a suture into and back out of the tissue proximate the target site. The method can further include advancing the stimulation assembly along the suture until an electrode of the stimulation assembly contacts the tissue at the target site. Lastly, the method can include securing the suture to itself at a securement region proximal of the receiver-stimulator, and severing the suture proximal of the securement region. In some embodiments, the method can include advancing the stimulation assembly at least partially through a catheter while advancing the stimulation electrode along the suture. After advancing the stimulation assembly along the suture until the electrode of the stimulation assembly contacts the tissue at the target site, the method can then include directing acoustic energy toward the stimulation assembly from an acoustic transducer positioned at a distal portion of the catheter. The stimulation assembly can receive the acoustic energy and convert the acoustic energy to electrical energy for output to the tissue via the electrode. In some aspects of the present technology, the output electrical energy can stimulate the tissue and/or can be used to determine one or more one or more electrical timing parameters and/or pacing threshold parameters of the target site.
Specific details of several embodiments of the present technology are described herein with reference to
The terminology used in the description presented below is intended to be interpreted in its broadest reasonable manner, even though it is being used in conjunction with a detailed description of certain specific embodiments of the disclosure. Certain terms can even be emphasized below; however, any terminology intended to be interpreted in any restricted manner will be overtly and specifically defined as such in this Detailed Description section.
The accompanying Figures depict embodiments of the present technology and are not intended to be limiting of its scope. The sizes of various depicted elements are not necessarily drawn to scale, and these various elements can be arbitrarily enlarged to improve legibility. Component details can be abstracted in the Figures to exclude details such as position of components and certain precise connections between such components when such details are unnecessary for a complete understanding of how to make and use the present technology. Many of the details, dimensions, angles, and other features shown in the Figures are merely illustrative of particular embodiments of the disclosure. Accordingly, other embodiments can have other details, dimensions, angles, and features without departing from the spirit or scope of the present technology.
In some embodiments, the system 100 can further include a programmer 130 in operable communication with the controller-transmitter 120. The programmer 130 can be positioned outside the body 104 and can be operable to program various parameters of the controller-transmitter 120 and/or to receive diagnostic information from the controller-transmitter 120. In some embodiments, the system 100 can further include a co-implant device 132 (e.g., an implantable cardioverter defibrillator (ICD) or pacemaker) coupled to pacing leads 134 for delivering stimulation pulses to one or more portions of the heart 102 other than the area stimulated by the receiver-stimulator 110. In other embodiments, the co-implant device 132 can be a leadless pacemaker which is implanted directly into the heart 102 to eliminate the need for separate pacing leads 134. The co-implant device 132 and the controller-transmitter 120 can be configured to operate in tandem and deliver stimulation signals to the heart 102 to cause a synchronized heartbeat. In some embodiments, the controller-transmitter 120 can receive signals (e.g., electrocardiogram signals) from the heart 102 to determine information related to the heart 102, such as a heart rate, heart rhythm, including the output of the pacing leads 134 located in the heart 102. In some embodiments, the controller-transmitter 120 can alternatively or additionally be configured to receive information (e.g., diagnostic signals) from the receiver-stimulator 110. The received signals can be used to adjust the ultrasound energy signals delivered to the receiver-stimulator 110.
The receiver-stimulator 110, the controller-transmitter 120, and/or the programmer 130 can include a machine-readable (e.g., computer-readable) or controller-readable medium containing instructions for generating, transmitting, and/or receiving suitable signals (e.g., stimulation signals, diagnostic signals). The receiver-stimulator 110, the controller-transmitter 120, and/or the programmer 130 can include one or more processor(s), memory unit(s), and/or input/output device(s). Accordingly, the process of providing stimulation signals and/or executing other associated functions can be performed by computer-executable instructions contained by, on, or in computer-readable media located at the receiver-stimulator 110, the controller-transmitter 120, and/or the programmer 130. Further, the receiver-stimulator 110, the controller-transmitter 120, and/or the programmer 130 can include dedicated hardware, firmware, and/or software for executing computer-executable instructions that, when executed, perform any one or more methods, processes, and/or sub-processes described herein. The dedicated hardware, firmware, and/or software also serve as “means for” performing the methods, processes, and/or sub-processes described herein.
In some embodiments, the system 100 can include several features generally similar or identical to those of the leadless tissue stimulation systems disclosed in (i) U.S. Pat. No. 7,610,092, filed Dec. 21, 2005, and titled “LEADLESS TISSUE STIMULATION SYSTEMS AND METHODS,” (ii) U.S. Pat. No. 8,315,701, filed Sep. 4, 2009, and titled “LEADLESS TISSUE STIMULATION SYSTEMS AND METHODS,” and/or (iii) U.S. Pat. No. 8,718,773, filed May 23, 2007, and titled “OPTIMIZING ENERGY TRANSMISSION IN A LEADLESS TISSUE STIMULATION SYSTEM.”
More specifically, in the illustrated embodiment the receiver-stimulator 210 includes a body 212 having a distal surface 213 (e.g., a distal portion) and a side surface 215. In some embodiments, the body 212 can have a generally cylindrical shape while, in other embodiments, the body 212 can have other shapes (e.g., including a rectangular, square, polygonal, rectilinear, irregular, and/or other cross-sectional shape). The receiver-stimulator 210 can further include an electrode 214 positioned at (e.g., coupled to, extending from) the distal surface 213 of the body 212 and a hook mechanism 216 (e.g., an anchor mechanism, a tether mechanism) positioned at the distal surface 213. In some embodiments the electrode 214 is a cathode and all or a portion of the body 212 of the receiver-stimulator 210 can comprise an anode. As described in detail above with reference to
In some embodiments, the receiver-stimulator 210 can include some features that are at least generally similar in structure and function, or identical in structure and function, to those of the receiver-stimulators disclosed in any of (i) U.S. Pat. No. 7,848,815, filed Sep. 4, 2009, and titled “IMPLANTABLE TRANSDUCER DEVICES”; (ii) U.S. Pat. No. 7,606,621, filed Dec. 21, 2005, and titled “IMPLANTABLE TRANSDUCER DEVICES”; (iii) U.S. Pat. No. 7,610,092, filed Dec. 21, 2005, and titled “LEADLESS TISSUE STIMULATION SYSTEMS AND METHODS”; (iv) U.S. Pat. No. 9,616,237, filed Sep. 30, 2013, and titled “SYSTEMS, DEVICES, AND METHODS FOR SELECTIVELY LOCATING IMPLANTABLE DEVICES”; (v) U.S. Pat. No. 9,343,654, filed Oct. 15, 2015, and titled “METHOD OF MANUFACTURING IMPLANTABLE WIRELESS ACOUSTIC STIMULATORS WITH HIGH ENERGY CONVERSION EFFICIENCIES”; and/or (vi) U.S. Pat. No. 9,283,392, filed Sep. 24, 2010, and titled “TEMPORARY ELECTRODE CONNECTION FOR WIRELESS PACING SYSTEMS,” each of which is incorporated herein by reference in its entirety.
In the illustrated embodiment, the hook mechanism 216 includes a first portion 217 secured to and/or proximate to the distal surface 213 of the body 212 and a second portion 219 that is free. The hook mechanism 216 can have a curved shape between the first and second portions 217, 219 such that, for example, the second portion 219 points at least partially back toward the body 212. The curve of the hook mechanism 216 can be circular, oval, polygonal, and/or other shapes. In the illustrated embodiment, the hook mechanism 216 lays in a plane that extends generally orthogonal to the distal surface 213. In some embodiments, the second portion 219 of the hook mechanism 216 can have a sharpened distal tip or terminus to enable the hook mechanism 216 to penetrate tissue. The hook mechanism 216 can be formed of a metal, plastic, and/or suitably strong materials. In some embodiments, the hook mechanism 216 is rigid such that the hook mechanism 216 is not configured to move substantially relative to the body 212. In other embodiments, the hook mechanism 216 can be formed of a flexible material such that, for example, the hook mechanism 216 is biased in a direction toward the body 212 and the electrode 214.
In some embodiments, the first portion 217 of the hook mechanism 216 is not permanently secured to the body 212 such that the hook mechanism 216 is movable relative to the body 212. For example, the hook mechanism 216 can be movable from a delivery position (not shown) in which all or a portion of the hook mechanism 216 is positioned within the body 212 or against an outer surface of the body 212, to a deployed position shown in
When the receiver-stimulator 210 is implanted within a patient, the hook mechanism 216 is configured to secure the receiver-stimulator 210 in position relative to tissue of the patient such that the electrode 214 contacts the tissue.
In some embodiments, such as when the tissue 240 comprises cardiac tissue, the endocardial wall 242 can have a complex structure comprised of trabeculae, papillary muscles, chordae, etc., that define a fractal-like surface including various openings, depressions, caves, and the like. In some aspects of the present technology, after implantation the hook mechanism 216 is configured to pull the electrode 214 into proper contact with the endocardial wall 242, such as contact with the papillary muscles, to facilitate effective electrical stimulation thereof. For example, the hook mechanism 216 can position the electrode 214 for desired endocardial stimulation as opposed to mid-myocardial or other stimulation. Accordingly, in some aspects of the present technology the receiver-stimulator 210 is optimized for implantation at fascial pacing targets, such as the left bundle branch (LBB). In contrast, some known electrical stimulation electrodes include barbs or other poking mechanism that must be pushed into tissue to secure the electrode thereto. For example, such electrodes are often attached to a delivery system that must be deployed normal to (e.g., pushed inward at a 90° angle toward) the endocardial wall with sufficient force to secure the barb of the simulation electrode within the endocardial wall. In contrast to the present technology, such systems can require complex delivery systems to achieve the required normal positioning, and such anchoring techniques can reduce the likelihood of properly positioning the stimulation electrode relative to the endocardial wall. For example, if the wall is thin, pushing the barb inward into the wall can stretch and distend the wall and increase the likelihood that the barb penetrates the wall entirely. Likewise, pushing the barb inward may cause a stimulating tip of the stimulation electrode to be positioned too deep inside the wall where stimulation may not be purely endocardial—which is expected to be less effective than purely endocardial stimulation.
However, in the illustrated embodiment the electrode 314 and the hook mechanism 316 extend from the side surface 315. The hook mechanism 316 can include a first portion 317 secured to the side surface 315 of the body 312 and a second portion 319 that is free. When the receiver-stimulator 310 is implanted within a patient, the hook mechanism 316 is configured to secure the receiver-stimulator 310 in position relative to tissue of the patient such that the electrode 314 contacts the tissue. For example, the hook mechanism 316 can pull the electrode 314 into contact (e.g., electrical engagement) with the tissue (e.g., the endocardial wall 242 of
Referring to
In some embodiments, after securing the suture 460 to the tissue 440, the suture 460 can be tightened to bring the electrode 456 into firm contact with the wall 442 at the target site. The electrode 456 can then be controlled again to confirm electrical timing parameters and/or pacing threshold parameters at the target site. In some aspects of the present technology, the location of the electrode 456 after deployment of the suture 460 can be substantially the same as the final implantation location of the receiver-stimulator 410 (
In some embodiments, the delivery system 450 can include various features configured to facilitate a final confirmation of electrical timing parameters and/or pacing threshold parameters at the location of the receiver-stimulator 410. More specifically, referring first to
Referring to
In some embodiments, the receiver-stimulator 410 can include a voltage regulator configured to limit the electrical output of the electrode 414 to at or below a predetermined level (e.g., about 3 volts). In some embodiments, the receiver-stimulator 410 and the voltage limiter can be least generally similar in structure and function, or identical in structure and function, to the receiver-stimulators and/or voltage regulators disclosed in U.S. patent application Ser. No. 16/773,599, filed Jan. 27, 2020, and titled “DEVICES, SYSTEMS, AND METHODS FOR CARDIAC RESYNCHRONIZATION THERAPY,” which is incorporated herein by reference in its entirety. In such embodiments, the acoustic transducer 468 can be configured to output the acoustic energy 469 at a level sufficient to trigger the maximum voltage output of the receiver-stimulators (e.g., 3 volts). In some aspects of the present technology, this can allow the controller-transmitter 120 (
The following examples are illustrative of several embodiments of the present technology:
1. A stimulation assembly implantable within a heart of a patient, comprising:
2. The stimulation assembly of example 1 wherein the body has a cylindrical shape including a distal surface and a side surface, and wherein the hook mechanism extends from the distal surface.
3. The stimulation assembly of example 2 wherein the electrode extends from the distal surface.
4. The stimulation assembly of example 1 wherein the body has a cylindrical shape including a distal surface and a side surface, and wherein the hook mechanism extends from the side surface.
5. The stimulation assembly of example 4 wherein the electrode extends from the side surface.
6. The stimulation assembly of example 4 or example 5 wherein the hook mechanism extends within a plane extending generally parallel to the distal surface.
7. The stimulation assembly of any one of examples 1-6 wherein the hook mechanism has a first end portion coupled to the body and a second end portion that is free, and wherein the hook mechanism has a curved shape between the first and second end portions.
8. The stimulation assembly of example 7 wherein the second portion of the hook mechanism points at least partially back toward the body.
9. The stimulation assembly of any one of examples 1-8 wherein hook mechanism is movable between a delivery position and a deployed position, wherein the hook mechanism is positioned at least partially within the body in the delivery position, and wherein the hook mechanism extends from the body in the deployed position.
10. A method of implanting a stimulation assembly at a target site of cardiac tissue within a patient, the method comprising:
11. The method of example 10 wherein the method further comprises detecting one or more electrical timing parameters and/or pacing threshold parameters at the target site.
12. The method of example 11 wherein detecting the one or more electrical timing parameters and/or pacing threshold parameters includes positioning an electrode of a catheter in contact with the target site before threading the suture into and back out of the tissue.
13. The method of example 12 wherein threading the suture into and back out of the tissue includes advancing the suture out of the catheter, into the tissue, back out of the tissue, and then back into the catheter.
14. The method of any one of examples 10-13 wherein the stimulation assembly includes a body and a plurality of guides coupled to the body, wherein the method further comprises threading the suture trough the guides, and wherein advancing the stimulation assembly along the suture includes tracking the guides along the suture.
15. The method of any one of examples 10-14 wherein securing the suture to itself includes tying or crimping the suture.
16. The method of any one of examples 10-15 wherein the method further comprises:
17. A system for stimulating cardiac tissue of a patient, comprising:
18. The system of example 17, further comprising the stimulation assembly, wherein the stimulation assembly includes circuitry configured to receive the acoustic energy, convert the acoustic energy to electrical energy, and output the electrical energy to the electrode for delivery to the cardiac tissue.
19. The system of example 18 wherein the circuitry of the stimulation assembly further includes a voltage limiter configured to limit a voltage of the electrical energy output to the electrode to at or below a predetermined level.
20. The system of example 19 wherein the acoustic transducer is configured to generate the acoustic energy at a level sufficient to cause the circuitry of the stimulation assembly to output the electrical energy at the predetermined level.
The above detailed description of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. For example, although steps are presented in a given order, alternative embodiments can perform steps in a different order. Likewise, the various electronic components and functions can be separated into more or fewer electronic circuit elements and/or functional blocks. The various components and/or functionalities of the embodiments described herein can also be combined to provide further embodiments.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology. Where the context permits, singular or plural terms can also include the plural or singular term, respectively.
Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications can be made without deviating from the technology. Further, while advantages associated with some embodiments of the technology have been described in the context of those embodiments, other embodiments can also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
This application claims the benefit of U.S. Provisional Patent Application No. 63/066,694, filed Aug. 17, 2020, and titled “ENDOCARDIAL PACING ELECTRODES WITH TISSUE ENGAGEMENT MECHANISMS,” which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3659615 | Enger | May 1972 | A |
3693627 | Berkovits | Sep 1972 | A |
3698398 | Berkovits | Oct 1972 | A |
3735756 | Richards et al. | May 1973 | A |
3832994 | Bicher et al. | Sep 1974 | A |
3857382 | Williams et al. | Dec 1974 | A |
3939844 | Peuignot et al. | Feb 1976 | A |
3942534 | Allen et al. | Mar 1976 | A |
4181133 | Kolenik et al. | Jan 1980 | A |
4256115 | Bilitch | Mar 1981 | A |
4265228 | Zoll | May 1981 | A |
4280502 | Baker, Jr. et al. | Jul 1981 | A |
4306560 | Harris | Dec 1981 | A |
4561442 | Vollmann et al. | Dec 1985 | A |
4577633 | Forester et al. | Mar 1986 | A |
4690144 | Rise et al. | Sep 1987 | A |
4830006 | Haluska et al. | May 1989 | A |
5018523 | Bach, Jr. et al. | May 1991 | A |
5063928 | Grevis et al. | Nov 1991 | A |
5103129 | Slayton et al. | Apr 1992 | A |
5113859 | Funke | May 1992 | A |
5141588 | VanBuskirk | Aug 1992 | A |
5165403 | Mehra | Nov 1992 | A |
5170784 | Ramon et al. | Dec 1992 | A |
5174289 | Cohen | Dec 1992 | A |
5186177 | O'Donnell et al. | Feb 1993 | A |
5193539 | Schulman et al. | Mar 1993 | A |
5292338 | Bardy et al. | Mar 1994 | A |
5377166 | Kuhn | Dec 1994 | A |
5405367 | Schulman et al. | Apr 1995 | A |
5411535 | Fujii et al. | May 1995 | A |
5433731 | Hoegnelid et al. | Jul 1995 | A |
5590657 | Cain et al. | Jan 1997 | A |
5674251 | Combs et al. | Oct 1997 | A |
5749909 | Schroeppel et al. | May 1998 | A |
5751539 | Stevenson et al. | May 1998 | A |
5757104 | Getman et al. | May 1998 | A |
5766227 | Nappholz et al. | Jun 1998 | A |
5800464 | Kieval | Sep 1998 | A |
5814089 | Stokes et al. | Sep 1998 | A |
5817130 | Cox et al. | Oct 1998 | A |
5844349 | Oakley et al. | Dec 1998 | A |
5871506 | Mower | Feb 1999 | A |
5879303 | Averkiou et al. | Mar 1999 | A |
5935158 | Holmstrom et al. | Aug 1999 | A |
5978204 | Stevenson et al. | Nov 1999 | A |
5998910 | Park et al. | Dec 1999 | A |
6037704 | Welle | Mar 2000 | A |
6070101 | Struble et al. | May 2000 | A |
6078837 | Peterson et al. | Jun 2000 | A |
6110098 | Renirie et al. | Aug 2000 | A |
6141588 | Renirie et al. | Aug 2000 | A |
6223079 | Bakels et al. | Apr 2001 | B1 |
6233484 | Ben-Haim et al. | May 2001 | B1 |
6264611 | Ishikawa et al. | Jul 2001 | B1 |
6330475 | Renirie et al. | Dec 2001 | B1 |
6366816 | Marchesi | Apr 2002 | B1 |
6408205 | Renirie et al. | Jun 2002 | B1 |
6424234 | Stevenson et al. | Jul 2002 | B1 |
6425869 | Rafter et al. | Jul 2002 | B1 |
6439236 | Porter et al. | Aug 2002 | B1 |
6445953 | Bulkes et al. | Sep 2002 | B1 |
6464680 | Brisken et al. | Oct 2002 | B1 |
6496715 | Lee et al. | Dec 2002 | B1 |
6527729 | Turcott | Mar 2003 | B1 |
6534895 | Kadota et al. | Mar 2003 | B2 |
RE38119 | Mower | May 2003 | E |
6628989 | Penner et al. | Sep 2003 | B1 |
6645145 | Dreschel et al. | Nov 2003 | B1 |
6647292 | Bardy et al. | Nov 2003 | B1 |
6654638 | Sweeney | Nov 2003 | B1 |
6671547 | Lyster et al. | Dec 2003 | B2 |
6834204 | Osteroff et al. | Jan 2004 | B2 |
6707230 | Smith et al. | Mar 2004 | B2 |
6721597 | Bardy et al. | Apr 2004 | B1 |
6728576 | Thompson et al. | Apr 2004 | B2 |
6754528 | Bardy et al. | Jun 2004 | B2 |
6754531 | Kroll et al. | Jun 2004 | B1 |
6764446 | Wolinsky et al. | Jul 2004 | B2 |
6788974 | Bardy et al. | Sep 2004 | B2 |
6795732 | Stadler et al. | Sep 2004 | B2 |
6856835 | Bardy et al. | Feb 2005 | B2 |
6970742 | Mann et al. | Nov 2005 | B2 |
7006864 | Echt et al. | Feb 2006 | B2 |
7010350 | Kralik | Mar 2006 | B2 |
7043292 | Tarjan et al. | May 2006 | B2 |
7050849 | Echt et al. | May 2006 | B2 |
7160258 | Imran et al. | Jan 2007 | B2 |
7184830 | Echt et al. | Feb 2007 | B2 |
7200437 | Nabutovsky | Apr 2007 | B1 |
7283874 | Penner et al. | Oct 2007 | B2 |
7349740 | Soykan et al. | Mar 2008 | B2 |
7489967 | Von Arx et al. | Feb 2009 | B2 |
7499759 | Coe | Mar 2009 | B2 |
7558631 | Cowan et al. | Jul 2009 | B2 |
7606621 | Brisken et al. | Oct 2009 | B2 |
7610092 | Cowan et al. | Oct 2009 | B2 |
7751881 | Cowan et al. | Jul 2010 | B2 |
7848815 | Brisken et al. | Dec 2010 | B2 |
7890173 | Brisken et al. | Feb 2011 | B2 |
7894907 | Cowan et al. | Feb 2011 | B2 |
7996087 | Cowan et al. | Aug 2011 | B2 |
8315701 | Cowan et al. | Nov 2012 | B2 |
8718773 | Willis et al. | May 2014 | B2 |
9008776 | Cowan et al. | Apr 2015 | B2 |
9283392 | Moore et al. | Mar 2016 | B2 |
9343654 | Moore et al. | May 2016 | B2 |
9616237 | Pare et al. | Apr 2017 | B2 |
9731138 | Stadler et al. | Aug 2017 | B1 |
11266845 | Kim et al. | Mar 2022 | B2 |
20020077673 | Penner et al. | Jun 2002 | A1 |
20030013974 | Natarjan et al. | Jan 2003 | A1 |
20030069625 | Ley et al. | Apr 2003 | A1 |
20040015104 | Goldberger | Jan 2004 | A1 |
20040162501 | Imran et al. | Aug 2004 | A1 |
20040167580 | Mann et al. | Aug 2004 | A1 |
20040172083 | Penner et al. | Sep 2004 | A1 |
20040204744 | Penner et al. | Oct 2004 | A1 |
20040260346 | Overall et al. | Dec 2004 | A1 |
20050070962 | Echt et al. | Mar 2005 | A1 |
20060009831 | Lau et al. | Jan 2006 | A1 |
20060106442 | Richardson et al. | May 2006 | A1 |
20060135999 | Bodner et al. | Jun 2006 | A1 |
20060155338 | Mongeon | Jul 2006 | A1 |
20060161061 | Echt et al. | Jul 2006 | A1 |
20060224067 | Giftakis et al. | Oct 2006 | A1 |
20060241701 | Markowitz et al. | Oct 2006 | A1 |
20070032749 | Overall et al. | Feb 2007 | A1 |
20070088394 | Jacobson | Apr 2007 | A1 |
20070088397 | Jacobson | Apr 2007 | A1 |
20070088398 | Jacobson | Apr 2007 | A1 |
20070150009 | Kveen et al. | Jun 2007 | A1 |
20070232936 | Mann et al. | Oct 2007 | A1 |
20070260286 | Giftakis et al. | Nov 2007 | A1 |
20070265677 | Giftakis et al. | Nov 2007 | A1 |
20090082828 | Ostroff | Mar 2009 | A1 |
20180140850 | Linder et al. | May 2018 | A1 |
20180154164 | Bodner et al. | Jun 2018 | A1 |
20200338356 | Anderson et al. | Oct 2020 | A1 |
Number | Date | Country |
---|---|---|
4330680 | Mar 1995 | DE |
H06505662 | Jun 1994 | JP |
2002538934 | Nov 2002 | JP |
2003218805 | Jul 2003 | JP |
2004512106 | Apr 2004 | JP |
9961058 | Dec 1999 | WO |
03070323 | Aug 2003 | WO |
2004089465 | Oct 2004 | WO |
2004101062 | Nov 2004 | WO |
2004101062 | Mar 2005 | WO |
2009006531 | Jan 2009 | WO |
Entry |
---|
International Search Report and Written Opinion dated Jan. 11, 2022 in International Application No. PCT/US21/46376, 14 pages. |
Abraham et al., for the MIRACLE study group, “Cardiac Resynchronization in Chronic Heart Failure,” N Engl J Med, 2002;346: 1845-53. |
ACC/AHA Task Force on Practice Guidelines, “Evaluation and Management of Chronic Heart Failure in the Adult,” JACC 2002; 38: 2101-13. |
Allessie et al., “Regional Control of Atrial Fibrillation by Rapid Pacing in Conscious Dogs,” Circulation 1991 ;84: 1689-97. |
Ansalone et al., “Bi-ventricular pacing I heart failure:back to basics in the pathophysiology of left bundle branch block to reduce the number of nonresponders,” Am J Cardiol 2003;91 :55F-61F. |
Auricchio eta I., “Cardiac resynchronization therapy: current state of the art,” Circulation 2004; | 09:300-307. |
Bardy et al., “The Totally Subcutaneous ICD System (The S-ICD),” PCAE. 2002, 24, 578. |
Becker et al., “Suppression of Atrial Fibrillation by Multisite and Septal Pacing in a Novel Experimental Model”, Cardiovascular Research 2001;54:476-481. |
Bradley et al., “Suppression of Atrial Fibrillation by Multisite and Septal Pacing in a Novel Experimental Model,” Cardiovascular Research 2001; 54(2): 476-481. |
Camm et al., Chaper 6: Nonpharmaceutical treatment of atrial fibrillation, In Atrial Fibrillation. Facts from Yesterday—Ideas for tomororw. Future Publishing Company, Inc., Armonk, NY, 1994, pp. 125-147. |
Dalecki et al., “Effects of Pulsed Ultrasound on the Frog Heart: I. Thresholds for Changes in Cardiac Rhythm and Aortic Pressure,” Ultrasound in Med. & Biol. 1993; 19: 385-390. |
Dalecki et al., “Effects of Pulsed Ultrasound on the Frog Heart: II. An Investigation of Heating as a Potential Mechanism,” Ultrasound in Med. & Biol. 1993; 19: 391-398. |
Dalecki et al., “Thresholds for premature ventricular contractions in frog hearts exposed to lithotripter fields,” Ultrasound in Med. & Biol. 1991; 17:341-346. |
Daoud et al., “Implantation Techniques and Chronic Lead Parameters of Bivnetricular Pacing Dual-chambers Defibrillators,” J Cardiovasc Electrophysiology 2002; 13: 964-970. |
Daubert et al., “Permanent Left Ventricular Pacing with Transvenous Leads Inserted Into the Coronary Veins,” PACE 1998; 21: 239-245. |
Daubert et al., “Use of Specifically Designed Coronary Sinus Leads for Permanent Left Ventricular Pacing: Preliminary Experience,” PACE 1997; 20: II-NASPE Abstract 17, Apr. 1997. |
DAVID Trial Investigators, “The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial,” JAMA 2002;288:3115-3123. |
Deshmukh et al., “Direct His-bundle pacing: present and future,” PACE 2004;27 [Pt.II]:862-70. |
Ellenbogen et al., “Detection and Management of an Implantable Cardioverter Defibrillator Lead Failure,” JACC 2003; 41: 73-80. |
European Search Report and Search Opinion dated Mar. 23, 2012 in European Patent Application No. 07841364.8. |
European Search Report and Search Opinion dated May 4, 2010 in European Patent Application No. 05855143, 8 pages. |
Extended European Search Report dated Mar. 26, 2008 in European Patent Application No. 05855395.9, 6 pages. |
Feldman et al., “Comparison of medical therapy, resynchronization and defibrillation therapies in heart failure trial (COMPANION),” Presented at ACC 2003 Laet Breaking Clinical Trials, 1 page. |
Franz, “Mechano-electrical feedback in ventricular myocardium,” Cardiovascular Research. 1996; 32: 15-24. |
Gregoratos et al., ACC/AHA/NASPE 2002 guideline update for implanation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002; 106: 2145-2161. |
Hu et al., “Stretch-Activated lon Channels in the Heart,” J. Mol. Cell Cardiol. 1997; 29: 1511-1523. |
International Search Report and Written Opinion dated Apr. 7, 2008 in International Application No. PCT/US07/76812, 8 pages. |
International Search Report and Written Opinion dated Jun. 23, 2008 in International Application No. PCT/US05/46532, 8 pages. |
Johnson et al., Adaptive Pacing during Ventricular Fibrillation, PACE 2003;26:1824-36. |
Kalman et al., “Regional Entrainment of Atrial Fibrillation in Man”, J Cardiovasc Electrophysiol 1991;7:867-76. |
Kass et al., “Improved Left Ventricular Mechanics from Acute VDD Pacing in Patients with Dilated Cardiomyopathy and Ventricular Conduction Delay,” Circulation 1999;99: 1567-73. |
Kenknight B.H. et al., “Regional Capture of Fibrillating Ventricular Myocardium” Circ Res 1999;77:849-55. |
Kohl et al., “Stretch-Induced Changes in Heart Rate and Rhythm: Clinical Observations, Experiments and Mathematical Models.” Progress in Biophysics & Molecular Biology, 1999; 91: 91-138. |
Kohl et al., “Sudden Cardiac Death by Commotio Cordis: Role of Merchano-Electrical Feedback,” Cardiovascular Research, 2001; 50: 280-289. |
Leclercq et al., “Acute Hemodynamic Effects of Biventricular DDD Pacing in Patients with End-Stage Heart Failure,” JACC 1998; 32: 1825-1831. |
Leclercq et al., “Systolic Improvement and Mechanical Resynchronization does not Require Electrical Synchrony in the Dilated Failing Heart with Left-Bundle-Branch Block,” Circulation 2002; 106: 1760-1763. |
Leclercq et al., “Is Dual Site Better than Single Site Atrial Pacing in the Prevention of Atrial Fibrillation?” PACE 2000;23 2102-7. |
Lee et al., “Effect of implantable Defibrillators of Arrhythmic Events and Mortality in the Multicenter Unsustained Tachycardia Trial,” Circulation. 2002; 106: 233-238. |
Linde et al., “Long-Term Benefits of Biventricular Pacing in Congestive Heart Failure: From the Multisite Stimulation in Cardiomyopathy (MUSTIC) Study,” J Am Coll Cardiol 2002; 40: 111-118. |
Miracle Trial Investigators, “Combined Cardiac Resynchronization and Implantable Cardioversion Defibrillation in Advanced Heart Failure:the Miracle ICD Trial,” JAMA 2003; 289: 2685-2694. |
Mirza et al., “Biatrial Pacing for Paroxysmal Atrial Fibrillation”, J Am Coll Cardiol 2002;40:457-463. |
Moss et al., “Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction,” N Engl J Med. 2002; 346: 877-933. |
Niehaus et al., “Non-Contact Cardiac Stimulation with locused Ultrasound Pulses,” PACE 2003: 216: 1023. |
Nielsen et al., “A Randomized Comparison of Atrial and Dual-Chambered Pacing in 177 Consecutive Patients with Sick Sinus Syndrome,” J Am Coll Cardiol 2003; 42: 614-623. |
Nolte et al., “Mechanically Induced Ventricular Extrasystoles in the Isolated Perfused Guinea-Pig Heart,” Arzneim.-Forsch/drug Research. 1987; 37(11): 1025-1029. |
Office Action dated Jan. 3, 2012 for U.S. Appl. No. 12/554,257. |
Office Action dated May 14, 2012 for U.S. Appl. No. 12/554,257. |
Office Action dated Jun. 23, 2008 for U.S. Appl. No. 11/535,857. |
Office Action dated Sep. 14, 2010 for U.S. Appl. No. 12/554,234. |
Office Action dated Nov. 12, 2008 for U.S. Appl. No. 11/535,857. |
Peschar et al., “Left ventricular septal and apex pacing for optimal pump function in canine hearts,” J Am Coll Cardiol 2003;41:1218-26. |
Reiter et al., “Effects of Mechano-Electrical Feedback: Potential Arrhythmogenic Influence in Patients with Congestive Heart Failure,” Cardiovascular Research, 1996; 32: 44-51. |
Smailys et al., “Investigation of the Possibilities of cardiac Defibrillation by Ultrasound,” Resuscitation, 1981; 9: 233-242. |
Sowton., “Clinical Results with the Tachylog Antitachycardia Pacemaker”, PACE 1984;7(Part 11):1313-1317. |
Tacker, Chapter 1: Fibrillation causes and criteria for defibrillation. In Defibrillation of the Heart. Tacker, WA, ed. Mosby-Year Book, Inc., St. Louis, Missouri, 1994, pp. 1-14. |
The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators, “A Comparison of Antiarrhythmic Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near Fatal Ventricular Arrhythmias,” N Engl J Med, 1997; 337: 1576-1583. |
Valls-Bertaults et al., “Adverse Events with Transvenous Left Ventricular Pacing in Patients with Severe Heart Failure: Early Experience from a Single Centre,” Europace, 2001; 3: 60-63. |
Warren et al., “Clinical Evaluation of Automatic Tachycardia Diagnosis by an Implanted Device”, PACE 1986;9 (Part 11):1079-1083. |
Number | Date | Country | |
---|---|---|---|
20220047865 A1 | Feb 2022 | US |
Number | Date | Country | |
---|---|---|---|
63066694 | Aug 2020 | US |